Skip to main
OKUR

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics is well-positioned in the biopharmaceutical industry with its precision medicine approach and structure-based drug design platform, which sets it apart from its competitors. Its focus on targeting oncogenic PI3Kα, particularly the H1047R mutation, presents a strong clinical and commercial potential, and the company's expansion into other mutations and indications further supplements its growth prospects. With a strong balance sheet and a cash runway into 2029, OnKure has the financial stability to execute its pipeline and achieve its goals.

Bears say

OnKure Therapeutics is trading at a market value of $834M, implying a 12-month price objective of $21 per share. However, the financial outlook for this company is negative due to several factors, including the low probability of approval for their lead asset, OKI-345, delays in advancing pipeline candidates, and potential competition in the market. Additionally, there is a risk of long-term dilution due to the accretion of redeemable convertible preferred stock.

OKUR has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Buy based on their latest research and market trends.

According to 2 analysts, OKUR has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.